Since its inception in 1998, TYRX scientists, engineers and marketers have focused on a singular goal — creating unique, cost-effective solutions that address surgical-site infections (SSIs) and inflammatory tissue-reaction associated with implanted medical devices. TYRX is an FDA registered, ISO 13485:2003 certified medical device manufacturer of drug-device combination products utilizing novel polymer technology, including a world-wide license from Rutgers, The State University of New Jersey, covering a broad range of resorbable materials and drug delivery technology. Additionally, TYRX has licensed from Baylor College of Medicine and The University of Texas M. D. Anderson Cancer Center combination drug patents and associated technologies to address the problem of postsurgical infection and fibrosis. TYRX is deploying its capabilities across a broad range of combination medical products.
Financials
| Date | Type | Amount | Investors | Valuation |
|---|---|---|---|---|
| 12/01/10 | Other | 20M | HLM Venture Partners, Clarus Ventures, Pappas Ventures | Unknown |